Bayesian method application: Integrating mathematical modeling into clinical pharmacy through vancomycin therapeutic monitoring.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101626369 Publication Model: Print Cited Medium: Internet ISSN: 2052-1707 (Electronic) Linking ISSN: 20521707 NLM ISO Abbreviation: Pharmacol Res Perspect Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Hoboken, NJ] : John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics, [2013]-
    • Subject Terms:
      Vancomycin*/pharmacokinetics ; Pharmacy*; Adult ; Humans ; Child ; Bayes Theorem ; Anti-Bacterial Agents/therapeutic use ; Drug Monitoring/methods
    • Abstract:
      The most recent consensus guidelines for dosing and monitoring vancomycin recommended the use of area-under-the-curve with Bayesian estimation for therapeutic monitoring. As this is a modern concept in the practice of clinical pharmacy, the main objective of this review is to introduce the fundamentals of Bayesian estimation and its mathematical application as it relates to vancomycin therapeutic drug monitoring. In addition, we aim to identify pharmacokinetic (PK) software programs that incorporate Bayesian estimation for vancomycin dosing and to describe the PK models utilized in those software programs for the adult population. Twelve software programs that utilize Bayesian estimation were identified, which included: Adult and Pediatric Kinetics, Best Dose, ClinCalc, DoseMeRx, ID-ODS, InsightRx, MwPharm++, NextDose, PrecisePK, TDMx, Tucuxi, and VancoCalc. The software programs varied in the population PK models used as the Bayesian a priori. With the presence of various vancomycin Bayesian software programs, it is important to choose those that utilize PK models reflective of the specific patient population.
      (© 2022 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.)
    • References:
      Antimicrob Agents Chemother. 2017 Apr 24;61(5):. (PMID: 28289024)
      Infect Dis (Auckl). 2020 Sep 25;13:1178633720952078. (PMID: 33029073)
      Ther Drug Monit. 2021 Feb 1;43(1):139-140. (PMID: 33009289)
      PLoS One. 2019 May 14;14(5):e0216801. (PMID: 31086400)
      Am J Epidemiol. 1995 Feb 1;141(3):263-72. (PMID: 7840100)
      J Antimicrob Chemother. 2016 Feb;71(2):471-9. (PMID: 26568565)
      Antimicrob Agents Chemother. 1988 Jun;32(6):848-52. (PMID: 3415206)
      J Pharm Pharmacol. 2019 Jun;71(6):945-955. (PMID: 30873627)
      Am J Health Syst Pharm. 2019 Jun 3;76(12):889-894. (PMID: 31063582)
      Clin Pharmacokinet. 2020 Jun;59(6):671-698. (PMID: 32020531)
      Clin Transl Sci. 2022 Apr;15(4):942-953. (PMID: 35170243)
      J Antimicrob Chemother. 2009 May;63(5):1050-7. (PMID: 19299472)
      Pharmacotherapy. 2015 Feb;35(2):127-39. (PMID: 25644478)
      Pharmacotherapy. 2020 Mar;40(3):211-220. (PMID: 31957057)
      Br J Clin Pharmacol. 2020 Dec;86(12):2497-2506. (PMID: 32415710)
      Antimicrob Agents Chemother. 1984 Apr;25(4):433-7. (PMID: 6732213)
      Br J Clin Pharmacol. 2010 Aug;70(2):201-12. (PMID: 20653673)
      Clin Pharmacokinet. 1992 Jun;22(6):447-67. (PMID: 1587057)
      Fundam Clin Pharmacol. 2002 Aug;16(4):253-62. (PMID: 12570013)
      Int J Appl Basic Med Res. 2012 Jan;2(1):3-6. (PMID: 23776799)
      Crit Care Med. 2021 Oct 1;49(10):e952-e960. (PMID: 33938713)
      Clin Microbiol Infect. 2019 Oct;25(10):1286.e1-1286.e7. (PMID: 30872102)
      Clin Pharm. 1985 May-Jun;4(3):311-5. (PMID: 4006395)
      J Clin Pharm Ther. 2006 Oct;31(5):447-54. (PMID: 16958822)
      Ther Drug Monit. 2022 Apr 1;44(2):241-252. (PMID: 34145165)
      Clin Pharmacol Ther. 1979 Sep;26(3):294-305. (PMID: 466923)
      Clin Pharmacokinet. 2014 Sep;53(9):849-61. (PMID: 25117184)
      Burns. 2010 Jun;36(4):469-76. (PMID: 19875238)
      J Clin Pharm Ther. 2009 Aug;34(4):473-83. (PMID: 19583681)
      Intern Med J. 2017 May;47(5):593-600. (PMID: 28503880)
      Antimicrob Agents Chemother. 2005 Dec;49(12):4934-41. (PMID: 16304155)
      BMC Infect Dis. 2021 Feb 6;21(1):153. (PMID: 33549035)
      Clin Pharmacokinet. 2019 Jun;58(6):767-780. (PMID: 30656565)
      Antimicrob Agents Chemother. 2018 Jan 25;62(2):. (PMID: 29203493)
      Antimicrob Agents Chemother. 2011 Jun;55(6):2704-9. (PMID: 21402850)
      Antimicrob Agents Chemother. 2014;58(1):309-16. (PMID: 24165176)
      Am J Health Syst Pharm. 2020 May 19;77(11):835-864. (PMID: 32191793)
      Antimicrob Agents Chemother. 2017 Dec 21;62(1):. (PMID: 29084753)
      J Pharm Pract. 2021 Apr 27;:8971900211012395. (PMID: 33902351)
      Clin Infect Dis. 2020 Apr 10;70(8):1536-1545. (PMID: 31157370)
      Ther Drug Monit. 2018 Apr;40(2):212-221. (PMID: 29470227)
      Pharmacol Res Perspect. 2022 Dec;10(6):e01026. (PMID: 36398492)
      J Antimicrob Chemother. 2018 Nov 1;73(11):3081-3086. (PMID: 30203073)
      Br J Clin Pharmacol. 2019 Jun;85(6):1215-1226. (PMID: 30768726)
      Antimicrob Agents Chemother. 2017 Nov 22;61(12):. (PMID: 28923869)
    • Contributed Indexing:
      Keywords: Bayes theorem; pharmacokinetics; therapeutic drug monitoring; vancomycin
    • Accession Number:
      6Q205EH1VU (Vancomycin)
      0 (Anti-Bacterial Agents)
    • Publication Date:
      Date Created: 20221118 Date Completed: 20221121 Latest Revision: 20230211
    • Publication Date:
      20240104
    • Accession Number:
      PMC9672880
    • Accession Number:
      10.1002/prp2.1026
    • Accession Number:
      36398492